Immunological characterization of a multi-epitope vaccine against Echinococcus granulosus based on the extracellular structural domain of CTLA-4
Abstract
PurposeThe aim of this study was to provide potential for the development of an efficient multi-epitope vaccine against Echinococcus granulosus by exploring the immunological properties and immune efficacy of the recombinant antigen CTLA-4IgV-EgG1Y162-2(4) for the effective prevention of E. granulosus.MethodsTarget antigen sequences were retrieved from NCBI. Epitopes of CTLA-4IgV-EgG1Y162-2(4) were predicted using IEDB and SYFPEITHI, and physicochemical properties and tertiary structure were analyzed via ProtParam, ProtScale, DNASTAR, and SWISS-MODEL. The recombinant plasmid was constructed, expressed in Escherichia coli BL21(DE3), and purified by Ni-NTA affinity chromatography, with identity confirmed by SDS-PAGE and Western blotting. Murine dendritic cells (DCs) were cultured with the recombinant protein for 24 h and analyzed by flow cytometry for maturation and antigen binding. Balb/c mice were immunized with the recombinant protein and adjuvant; DC maturation was assessed by flow cytometry, splenocyte proliferation was evaluated by CCK-8, and serum IFN-γ, IL-4, and IgG were assessed by enzyme-linked immunosorbent assay (ELISA). Immunized mice were challenged with E. granulosus; after 120 days, the cyst wet weight inhibition rate was calculated, and spleen DC maturation, Th1/Th2 profiles, and serum cytokines were analyzed.ResultsThe amino acid sequence of CTLA-4IgV-EgG1Y162-2(4) was obtained, and epitope analysis revealed six T-cell and B-cell co-associated epitopes, with no epitope displacement caused by the CTLA-4 extracellular region or GSGGSG linker. Bioinformatics tools successfully predicted its physicochemical properties and spatial structure. The recombinant plasmid was constructed and expressed in BL21 cells. The purified protein was confirmed by His antibody and showed specific Western blot reactivity with CE-infected sera. CTLA-4IgV-EgG1Y162-2(4) promoted DC maturation both in vitro and in vivo, enhanced splenocyte proliferation, and elevated IFN-γ, IL-4, and IgG levels. In the challenge experiment, this group showed lower infection rates and cyst wet weights, and higher Th1 and lower Th2 responses, with favorable IFN-γ/IL-4 profiles.ConclusionThis study substantiates that CTLA-4IgV-EgG1Y162-2(4) stands as a multi-epitope vaccine characterized by remarkable immunogenicity and antigenicity, thus furnishing an indispensable theoretical and empirical foundation for the management and treatment of cystic echinococcosis (CE).
Related
- Extracellular vesicles derived from Echinococcus granulosus hydatid cyst fluid may modulate liver fibrosis through 5-HT2B receptor
- Hydatid Cyst Fluid of Echinococcus granulosus Alleviates Experimental Ulcerative Colitis by Suppressing Inflammation and Oxidative Stress and Regulating the Gut Microbiota
- Preliminary analysis of the proportions and characteristics of dual TCR T cells and dual BCR B cells in echinococcus granulosus-infected mice using scRNA+TCR+BCR-seq
- Phylogenetic analysis of zoonotic Echinococcus granulosus sensu stricto in humans and domestic animals from Armenia and Türkiye
- A panel of five microsatellites as an alternative to mitogenome sequencing for investigating the genetic diversity of Echinococcus granulosus sensu stricto from global to farm scale
BibTeX
@article{li2026immunological,
title = {{Immunological characterization of a multi-epitope vaccine against Echinococcus granulosus based on the extracellular structural domain of CTLA-4}},
author = {Yanmin Li and Xizhi Ma and Haiying Jia and Jia Zheng and Nafei Chen and Wentao Zhou and Qiaoqiao Gong and Shangqi Zhao and Jianbing Ding and Xiaotao Zhou},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1947499},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1947499},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Immunological characterization of a multi-epitope vaccine against Echinococcus granulosus based on the extracellular structural domain of CTLA-4
AU - Yanmin Li
AU - Xizhi Ma
AU - Haiying Jia
AU - Jia Zheng
AU - Nafei Chen
AU - Wentao Zhou
AU - Qiaoqiao Gong
AU - Shangqi Zhao
AU - Jianbing Ding
AU - Xiaotao Zhou
PY - 2026
DA - 2026/10/30
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1947499
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1947499
AB - PurposeThe aim of this study was to provide potential for the development of an efficient multi-epitope vaccine against Echinococcus granulosus by exploring the immunological properties and immune efficacy of the recombinant antigen CTLA-4IgV-EgG1Y162-2(4) for the effective prevention of E. granulosus.MethodsTarget antigen sequences were retrieved from NCBI. Epitopes of CTLA-4IgV-EgG1Y162-2(4) were predicted using IEDB and SYFPEITHI, and physicochemical properties and tertiary structure were analyzed via ProtParam, ProtScale, DNASTAR, and SWISS-MODEL. The recombinant plasmid was constructed, expressed in Escherichia coli BL21(DE3), and purified by Ni-NTA affinity chromatography, with identity confirmed by SDS-PAGE and Western blotting. Murine dendritic cells (DCs) were cultured with the recombinant protein for 24 h and analyzed by flow cytometry for maturation and antigen binding. Balb/c mice were immunized with the recombinant protein and adjuvant; DC maturation was assessed by flow cytometry, splenocyte proliferation was evaluated by CCK-8, and serum IFN-γ, IL-4, and IgG were assessed by enzyme-linked immunosorbent assay (ELISA). Immunized mice were challenged with E. granulosus; after 120 days, the cyst wet weight inhibition rate was calculated, and spleen DC maturation, Th1/Th2 profiles, and serum cytokines were analyzed.ResultsThe amino acid sequence of CTLA-4IgV-EgG1Y162-2(4) was obtained, and epitope analysis revealed six T-cell and B-cell co-associated epitopes, with no epitope displacement caused by the CTLA-4 extracellular region or GSGGSG linker. Bioinformatics tools successfully predicted its physicochemical properties and spatial structure. The recombinant plasmid was constructed and expressed in BL21 cells. The purified protein was confirmed by His antibody and showed specific Western blot reactivity with CE-infected sera. CTLA-4IgV-EgG1Y162-2(4) promoted DC maturation both in vitro and in vivo, enhanced splenocyte proliferation, and elevated IFN-γ, IL-4, and IgG levels. In the challenge experiment, this group showed lower infection rates and cyst wet weights, and higher Th1 and lower Th2 responses, with favorable IFN-γ/IL-4 profiles.ConclusionThis study substantiates that CTLA-4IgV-EgG1Y162-2(4) stands as a multi-epitope vaccine characterized by remarkable immunogenicity and antigenicity, thus furnishing an indispensable theoretical and empirical foundation for the management and treatment of cystic echinococcosis (CE).
SN - 1664-3224
ER -